Non-small Cell Lung Cancer Stage IIIA Clinical Trial
— MIRACLEOfficial title:
A Machine Learning Approach to Identify Patients With Resected Non-small-cell Lung Cancer With High Risk of Relapse
Early-stage non small cell lung cancer represents 20-30% of all non small cell lung cancer and is characterized by a high survival probability after surgical resection. However, considering stage IA-IIIA non small cell lung cancer, a relapse rate of about 50% is observed, with a different survival probability on the basis of tumor node metastasis status, although patients within the same tumor node metastasis stage exhibit wide variations in recurrence rate. There are currently no validated prognostic biomarkers able to identify patients with a high risk of relapse.
Status | Recruiting |
Enrollment | 60 |
Est. completion date | October 30, 2026 |
Est. primary completion date | November 30, 2025 |
Accepts healthy volunteers | No |
Gender | All |
Age group | 18 Years and older |
Eligibility | Inclusion Criteria: - Patient with an early stage of non small cell lung cancer - Indication of surgical resection - Patient able to understand and give his consent - Patient affiliated to the health insurance Exclusion Criteria: - Patient with another cancer in the last 5 years - Patient with an allergy to the contrast medium - Patient under legal protection |
Country | Name | City | State |
---|---|---|---|
France | Julien MAZIERES | Toulouse |
Lead Sponsor | Collaborator |
---|---|
University Hospital, Toulouse |
France,
Type | Measure | Description | Time frame | Safety issue |
---|---|---|---|---|
Primary | Algorithm for disease free survival | Analysis on a training cohort of resected early-stage non small cell lung cancer | 18 months |
Status | Clinical Trial | Phase | |
---|---|---|---|
Not yet recruiting |
NCT04455594 -
Almonertinib Vs. Erlotinib/Chemotherapy for Neo-adjuVant Treatment of Stage IIIA-N2 EGFR-mutated NSCLC
|
Phase 2 | |
Recruiting |
NCT02977169 -
To Evaluate the Role of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
|
Phase 2 | |
Terminated |
NCT02974426 -
To Evaluate the Optimal Timing of Postoperative Radiotherapy in Patients With IIIA(N2) Non-Small Cell Lung Cancer
|
Phase 3 | |
Completed |
NCT01991418 -
Early Warning Study of Serum Thioredoixn Reductase Activity in Excised Non-small Cell Lung Cancers (EWSOTRILC)
|
N/A | |
Recruiting |
NCT01410214 -
Erlotinib Versus Vinorelbine/Cisplatin as Adjuvant Treatment in Stage IIIA NSCLC Patients With EGFR Mutations
|
Phase 2 | |
Recruiting |
NCT01926483 -
Phase II Trial of Regimen for Stage III (N2) NSCLC Using Induction Treatment Followed by Resection
|
Phase 2 | |
Recruiting |
NCT04716946 -
Treating Early-stage Non-Small Cell Lung Cancer With Durvalumab and Radiation Therapy
|
Phase 2 | |
Recruiting |
NCT06268613 -
A Study to Compare the Pharmacokinetics, Efficacy, Safety, and Immunogenicity of Pembrolizumab (SB27, EU Sourced Keytruda, and US Sourced Keytruda) in Subjects With Stage II-IIIA NSCLC Following Complete Resection and Adjuvant Platinum-based Chemotherapy
|
Phase 1 |